12 results about "Poliomyelitis" patented technology

The present application provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers. The present application also provides a method of treating a cancer in an individual afflicted with a cancer comprising administering to the individual a therapeutically effective amount of chimeric antigen receptor (CAR) NK or T cells.

This invention belongs to the field of biomedical technology, specifically disclosing a nanomicelle FluDox-MIC, its preparation method, and its uses. This nanomicelle is formed by the self-assembly of flumatinib and doxorubicin co-loaded in mPEG-DSPE, exhibiting pH-responsive release properties. Upon entering the tumor microenvironment, it releases the drug. The released flumatinib induces the degradation of the poliovirus receptor (PVR / CD155), relieving its inhibitory signal on NK cells and reactivating innate immune surveillance. Simultaneously, low-dose doxorubicin induces significant immunogenic cell death (ICD), initiating and amplifying tumor-specific T cell-mediated adaptive immunity. Through the synergistic activation of innate and adaptive immunity, the nanomicelle of this invention can effectively inhibit melanoma growth and overcome immunotherapy resistance, showing promising clinical application prospects.

This application provides a poliovirus and method for treating human glioma, comprising a composition of oncolytic poliovirus and an Ommaya capsule, a delivery method, and uses.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers.

The invention discloses a method for printing a human exoskeleton based on 3D. The method comprises the following steps: S1, performing three-dimensional scanning on the appearance shape of a human body; s2, performing transmission and three-dimensional construction on the scanned human body information; s3, three-dimensional design of the human exoskeleton; s4, human body exoskeleton printing is conducted through a 3D printer; s5, the entity obtained through 3D printing is polished; through three-dimensional scanning of the human body appearance shape, three-dimensional model construction of the human body exoskeleton and selection and use of the joint connection structures through the joint model library, the robot better fits the human body joint curvature, and through design of connection end points through the squatting and rising assisting module, installation and connection of a spring or a hydraulic mechanism are facilitated; and after the human exoskeleton is subjected to three-dimensional model scanning processing, the 3D printer is controlled to operate according to a three-dimensional model scanning result, so that the 3D printer can print the exoskeleton.

The invention provides a method for detecting residual blood through object surface disinfection wet tissue, and relates to the technical field of medical environment, medical equipment and equipment surface cleaning detection. After the object surface disinfection wet tissue with the residual blood detection function is used for collecting surface samples of a medical environment, a medical instrument and equipment, the residual blood pollution degree of the surfaces of the medical environment, the medical instrument and the equipment is qualitatively, semi-quantitatively and quantitatively judged according to the color change of the object surface disinfection wet tissue with the residual blood detection function. The semi-quantitative detection calibrator comprises multiple stages of color blocks and subdivision grids, and the residual blood volume is calculated by counting the area proportion of different color blocks through visual inspection; according to the quantitative detection AI rule, wet tissue images are scanned through photography and analysis equipment, software analyzes the mapping relation between pixel RGB values and standard concentration, the method is easy and convenient to operate, large-batch data can be rapidly processed, the cost is remarkably reduced, and the method is particularly suitable for rapid pollution evaluation of medical environments, medical instruments and equipment surfaces. Meanwhile, the pirameton can generate a composite reaction with other components in the object surface disinfection wet tissue with the residual blood detection function, so that the sterilization and disinfection capability of the product is improved; through detection, the killing rate of the object surface disinfection wet tissue with the residual blood detection function on microorganisms such as staphylococcus aureus, escherichia coli and pseudomonas aeruginosa within one minute is as high as 99.999%, and the killing rate of the object surface disinfection wet tissue on poliovirus is as high as 99.99%.

Arrays comprising probes from at least two polioviruses selected from poliovirus type 1, poliovirus type 2 and poliovirus type 3 are provided. Arrays comprising a plurality of probes comprising short peptide probes from at least one poliovirus are also provided. Methods of using the arrays, as well as kits and systems comprising the arrays are also provided.

The invention relates to a preparation method of a poliovirus solution, which comprises the following steps in sequence: a) providing cells which exist in a culture medium; b) regulating the cells to a proper cell density, and then contacting the poliovirus with the cells to obtain a mixed solution of the poliovirus and the cells; c) centrifuging the mixed solution, and collecting supernate; and d) purifying the supernate through a chromatographic step to obtain the poliovirus solution.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CD112, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.

Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3ζ segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FRα) and a segment that that can specifically bind to a human CD3ε segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.

Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.